Age, mean (range) | 58 | (44–67) |
Male sex, n (%) | 9 | (53) |
BMI, mean (range) | 27.2 | (17.5–35.6) |
HCV RNA IE/mL, median (range) | 2.6 × 106 | (2.8 × 105 - 16 × 106) |
HCV genotype, n (%) | ||
1a | 7 | (41) |
1b | 3 | (18) |
3a | 5 | (29) |
1a/1b/1× | 2 | (12) |
Descent | ||
European | 16 | (94) |
Middle Eastern | 1 | (6) |
Previous IFN treatment, n (%) | 11 | (65) |
Psychiatric side effects during IFN treatment, n | 6 | |
Liver cirrhosis, n (%) | 10 | (59) |
Child-Pugh A | 9 | |
Child-Pugh B | 1 | |
Current psychiatric morbidity, n (%) | 6 | (35) |
Any mood disorder | 4 | (24) |
Any substance abuse or dependencea | 2 | (12) |
Any anxiety disorder | 1 | (6) |
ADHDc | 2 | (12) |
Lifetime psychiatric morbidity, n (%) | 15 | (88) |
Any mood disorder | 10 | (59) |
Any psychotic disorderb | 1 | (6) |
Any substance abuse or dependence | 11 | (65) |
Any anxiety disorder | 6 | (35) |
Any eating disorder | 2 | (12) |
ADHDc | 2 | (12) |
Psychotropic medication | ||
Any psychotropic medication | 8 | (47) |
Antidepressants | 3 | (18) |
Benzodiazepines | 3 | (18) |
Benzodiazepine-like agents for sleep | 3 | (18) |
Central nervous system stimulants | 1 | (6) |
Buprenorphine | 2 | (12) |